Aclaris Therapeutics Inc. (ACRS) Financial Statements (2024 and earlier)

Company Profile

Business Address 701 LEE ROAD
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:181,900187,000210,800204,400229,800248,100
Cash and cash equivalents39,87839,04031,15044,72245,27761,653
Short-term investments79,22864,01288,625126,081172,294186,409
Other undisclosed cash, cash equivalents, and short-term investments62,79483,94891,02533,59712,22938
Receivables298346431686484597
Other undisclosed current assets(53,342)(64,278)(78,296)(20,725)1,2667,876
Total current assets:128,856123,068132,935184,361231,550256,573
Noncurrent Assets
Property, plant and equipment1,6201,7641,8991,5131,0991,145
Long-term investments and receivables62,77183,94490,99233,60212,242 
Long-term investments62,77183,94490,99233,60212,242 
Intangible assets, net (including goodwill) 2696,9176,9356,9546,9736,992
Intangible assets, net (excluding goodwill) 2696,9176,9356,9546,9736,992
Other noncurrent assets3,8892,6612,8883,2752,7322,922
Total noncurrent assets:68,54995,286102,71445,34423,04611,059
TOTAL ASSETS:197,405218,354235,649229,705254,596267,632
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities28,32424,80820,16915,45319,05216,821
Accounts payable8,8789,64811,4258,19010,3517,667
Accrued liabilities19,44615,1608,7447,2638,7019,154
Disposal group, including discontinued operation 2,2022,2022,2022,2022,2022,202
Other liabilities      
Other undisclosed current liabilities 426310458603684766
Total current liabilities:30,95227,32022,82918,25821,93819,789
Noncurrent Liabilities
Liabilities, other than long-term debt9,27434,70133,07034,63735,03728,005
Deferred income tax liabilities  367367367367367
Other liabilities3,0741,8341,9031,9701,5701,638
Business combination, contingent consideration, liability6,20032,50030,80032,30033,10026,000
Total noncurrent liabilities:9,27434,70133,07034,63735,03728,005
Total liabilities:40,22662,02155,89952,89556,97547,794
Equity
Equity, attributable to parent157,179156,333179,750176,810197,621219,838
Common stock111111
Additional paid in capital928,080926,766920,904887,638880,832875,982
Accumulated other comprehensive loss(106)(1,129)(1,111)(354)(897)(1,465)
Accumulated deficit(770,796)(769,305)(740,044)(710,475)(682,315)(654,680)
Total equity:157,179156,333179,750176,810197,621219,838
TOTAL LIABILITIES AND EQUITY:197,405218,354235,649229,705254,596267,632

Income Statement (P&L) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Revenues17,5709,2821,8692,5287,75319,018
Cost of revenue(725)(848)(1,042)(808)(877)(923)
Gross profit:16,8458,4348271,7206,87618,095
Operating expenses(41,489)(30,967)(33,592)(31,377)(28,218)(29,469)
Other undisclosed operating income (loss)20,597(9,044)950(261)(7,737)(9,500)
Operating loss:(4,047)(31,577)(31,815)(29,918)(29,079)(20,874)
Nonoperating income
(Other Nonoperating income)
2,1892,3162,2461,7581,444922
Loss from continuing operations before income taxes:(1,858)(29,261)(29,569)(28,160)(27,635)(19,952)
Other undisclosed income from continuing operations 367     
Loss from continuing operations:(1,491)(29,261)(29,569)(28,160)(27,635)(19,952)
Loss before gain (loss) on sale of properties:(19,952)
Net loss available to common stockholders, diluted:(1,491)(29,261)(29,569)(28,160)(27,635)(19,952)

Comprehensive Income ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net loss:(1,491)(29,261)(29,569)(28,160)(27,635)(19,952)
Other comprehensive income (loss)1,023(18)(757)543568(139)
Comprehensive loss, net of tax, attributable to parent:(468)(29,279)(30,326)(27,617)(27,067)(20,091)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: